Latest Revenue Guidance News

TZ Limited reports steady sales growth and new Microsoft contracts in Q1 FY2026, reaffirming its $17–21 million revenue guidance amid improving market conditions.

Cann Group Limited has executed a transformative debt restructure, reducing its $70 million debt by 81% and raising $9 million in fresh capital, setting the stage for a positive EBITDA turnaround in FY26.

Qoria Limited reported a strong start to FY2026, with annual recurring revenue climbing 25% year-on-year and record cash receipts of $46.3 million, prompting an upgrade to its full-year revenue guidance.

EROAD pivots strategically to prioritise ANZ electronic road user charging opportunities, revises FY26 guidance downward, and appoints John Scott as Executive Chair to steer growth.

Aroa Biosurgery delivered a robust September quarter with strong cash flow and record sales of its Myriad product, while reaffirming its FY26 revenue and EBITDA guidance. The company also highlighted a promising US Medicare reimbursement proposal for its Symphony product.

Telix Pharmaceuticals reports a robust 53% revenue jump in Q3 2025 and raises its full-year guidance, underpinned by key reimbursement wins and expanding clinical programs.

NRW Holdings has completed its acquisition of Fredon Industries, integrating 2,500 new employees and enhancing its electrical and mechanical services portfolio. The company has updated its FY26 guidance, projecting revenue above $4 billion and underlying EBITA between $255 million and $265 million.

Bravura Solutions has raised its FY26 revenue and cash EBITDA guidance, citing a strong British pound and increased project activity in EMEA as key growth drivers.

Telix Pharmaceuticals has secured FDA agreement on a resubmission plan for its glioma imaging agent TLX101-CDx, aiming for a Q4 2025 filing that includes additional efficacy data. The FDA signals likely expedited review, underscoring the unmet medical need.

Amaero Ltd has updated its FY2026 financial guidance, forecasting revenue between A$30 million and A$35 million; a staggering 800%-900% increase year-over-year; and announced a A$50 million capital raise to expand production capacity and reduce costs.

Biome Australia Limited projects its Q1 FY26 sales revenue to exceed $5.5 million, breaking its previous quarterly record and signaling continued momentum in the microbiome health sector.

Bioxyne Limited projects FY2026 revenue between $65 million and $75 million, driven by expansion in Australian medical cannabis and a landmark $5.8 million contract in Germany.